Inactive Instrument

Quotient Limited

U4W0

JE00BNNSZY03

Quotient : Presenting the AliveDx 2023 Sustainability Report

April 09, 2024 at 04:28 am EDT

At AliveDx, we understand that the success of our business is closely linked to the wellbeing of the communities in which we operate. Our goal is to advance sustainable practices in every aspect of our operations. We are pleased to present the AliveDx 2023 Sustainability Report as a testament to our dedication. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

Original Link
Permalink

Disclaimer

Quotient Ltd. published this content on 09 April 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 April 2024 08:27:08 UTC.

Latest news about Quotient Limited

Quotient Limited Appoints James Harman Gaudin to its Board of Directors	23-06-14	CI
Certain Ordinary Shares of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Certain Restricted Share Units of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Certain Options of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Certain Warrants of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Transcript : Quotient Limited, Q4 2022 Earnings Call, Jun 24, 2022	22-06-24
Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023	22-06-24	CI

Chart Quotient Limited

Duration

Period

More charts

Company Profile

Quotient Limited is a Switzerland-based diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Additionally The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

Sector

Pharmaceuticals

More about the company